Cannabis
May 13, 2026
When cannabis becomes medicine
The DOJ's narrow marijuana rescheduling order may deliver long-awaited tax relief for licensed medical operators, but in California it also reframes cannabis activity through the lens of traditional health care law, with immediate implications for MSOs, clinicians and investors.
Mehdi Sinaki
Senior Associate
Michelman & Robinson, LLP
Phone: (909) 730-5375
Email: msinaki@mrllp.com
On April 22, 2026, Acting Attorney General Todd Blanche signed a final order, announced the following day and effective upon Federal Register publication on April 28, placing two narrow categories of marijuana into Schedule III of the Controlled Substances Act: FDA-approved drug products containing marijuana and marijuana subject to a qualifying state-issued medical marijuana license. Adult-use cannabis was left untouched. Anything outside those two categories, including the ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In